🚀 VC round data is live in beta, check it out!
Karyopharm Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Karyopharm Therapeutics and similar public comparables like Sagimet Biosciences, Protalix, Tonix Pharmaceuticals, Corbus Pharmaceuticals and more.
Karyopharm Therapeutics Overview
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Founded
2008
HQ
Employees
228
Website
Sectors
Financials (LTM)
EV
$354M
Karyopharm Therapeutics Financials
Karyopharm Therapeutics reported last 12-month revenue of $144M.
In the same LTM period, Karyopharm Therapeutics generated $138M in gross profit and had net loss of ($176M).
Revenue (LTM)
Karyopharm Therapeutics P&L
In the most recent fiscal year, Karyopharm Therapeutics reported revenue of $146M and EBITDA of ($150M).
Karyopharm Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $144M | XXX | $146M | XXX | XXX | XXX |
| Gross Profit | $138M | XXX | $140M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 96% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($150M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (103%) | XXX | XXX | XXX |
| EBIT Margin | (63%) | XXX | (62%) | XXX | XXX | XXX |
| Net Profit | ($176M) | XXX | ($196M) | XXX | XXX | XXX |
| Net Margin | (123%) | XXX | (134%) | XXX | XXX | XXX |
| Net Debt | — | — | $166M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Karyopharm Therapeutics Stock Performance
Karyopharm Therapeutics has current market cap of $184M, and enterprise value of $354M.
Market Cap Evolution
Karyopharm Therapeutics' stock price is $8.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $354M | $184M | 12.2% | XXX | XXX | XXX | $-8.70 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKaryopharm Therapeutics Valuation Multiples
Karyopharm Therapeutics trades at 2.5x EV/Revenue multiple, and (2.4x) EV/EBITDA.
EV / Revenue (LTM)
Karyopharm Therapeutics Financial Valuation Multiples
As of April 11, 2026, Karyopharm Therapeutics has market cap of $184M and EV of $354M.
Equity research analysts estimate Karyopharm Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Karyopharm Therapeutics has a P/E ratio of (1.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $184M | XXX | $184M | XXX | XXX | XXX |
| EV (current) | $354M | XXX | $354M | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.4x) | XXX | XXX | XXX |
| EV/EBIT | (3.9x) | XXX | (3.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | 2.5x | XXX | XXX | XXX |
| P/E | (1.0x) | XXX | (0.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Karyopharm Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Karyopharm Therapeutics Margins & Growth Rates
Karyopharm Therapeutics' revenue in the last 12 month grew by 0%.
Karyopharm Therapeutics' revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $1.0M for the same period.
Karyopharm Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | (6%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (103%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 288% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 72% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 85% | XXX | 86% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 158% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Karyopharm Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sagimet Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Protalix | XXX | XXX | XXX | XXX | XXX | XXX |
| Tonix Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Corbus Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Acumen Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Karyopharm Therapeutics M&A Activity
Karyopharm Therapeutics acquired XXX companies to date.
Last acquisition by Karyopharm Therapeutics was on XXXXXXXX, XXXXX. Karyopharm Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Karyopharm Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKaryopharm Therapeutics Investment Activity
Karyopharm Therapeutics invested in XXX companies to date.
Karyopharm Therapeutics made its latest investment on XXXXXXXX, XXXXX. Karyopharm Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Karyopharm Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Karyopharm Therapeutics
| When was Karyopharm Therapeutics founded? | Karyopharm Therapeutics was founded in 2008. |
| Where is Karyopharm Therapeutics headquartered? | Karyopharm Therapeutics is headquartered in United States. |
| How many employees does Karyopharm Therapeutics have? | As of today, Karyopharm Therapeutics has over 228 employees. |
| Who is the CEO of Karyopharm Therapeutics? | Karyopharm Therapeutics' CEO is Richard Paulson. |
| Is Karyopharm Therapeutics publicly listed? | Yes, Karyopharm Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Karyopharm Therapeutics? | Karyopharm Therapeutics trades under KPTI ticker. |
| When did Karyopharm Therapeutics go public? | Karyopharm Therapeutics went public in 2013. |
| Who are competitors of Karyopharm Therapeutics? | Karyopharm Therapeutics main competitors are Sagimet Biosciences, Protalix, Tonix Pharmaceuticals, Corbus Pharmaceuticals. |
| What is the current market cap of Karyopharm Therapeutics? | Karyopharm Therapeutics' current market cap is $184M. |
| What is the current revenue of Karyopharm Therapeutics? | Karyopharm Therapeutics' last 12 months revenue is $144M. |
| What is the current revenue growth of Karyopharm Therapeutics? | Karyopharm Therapeutics revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Karyopharm Therapeutics? | Current revenue multiple of Karyopharm Therapeutics is 2.5x. |
| Is Karyopharm Therapeutics profitable? | No, Karyopharm Therapeutics is not profitable. |
| What is the current net income of Karyopharm Therapeutics? | Karyopharm Therapeutics' last 12 months net income is ($176M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.